AU2019417161B2 - Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease - Google Patents

Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease Download PDF

Info

Publication number
AU2019417161B2
AU2019417161B2 AU2019417161A AU2019417161A AU2019417161B2 AU 2019417161 B2 AU2019417161 B2 AU 2019417161B2 AU 2019417161 A AU2019417161 A AU 2019417161A AU 2019417161 A AU2019417161 A AU 2019417161A AU 2019417161 B2 AU2019417161 B2 AU 2019417161B2
Authority
AU
Australia
Prior art keywords
betamethasone
pharmaceutical composition
sodium
disease
ocular surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2019417161A
Other languages
English (en)
Other versions
AU2019417161A1 (en
Inventor
Kamran Hosseini
Richard L. Lindstrom
Dennis Elias Saadeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surface Ophthalmics Inc
Original Assignee
Surface Ophthalmics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surface Ophthalmics Inc filed Critical Surface Ophthalmics Inc
Publication of AU2019417161A1 publication Critical patent/AU2019417161A1/en
Application granted granted Critical
Publication of AU2019417161B2 publication Critical patent/AU2019417161B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2019417161A 2018-12-27 2019-12-04 Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease Ceased AU2019417161B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785312P 2018-12-27 2018-12-27
US62/785,312 2018-12-27
PCT/US2019/064371 WO2020139525A1 (en) 2018-12-27 2019-12-04 Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease

Publications (2)

Publication Number Publication Date
AU2019417161A1 AU2019417161A1 (en) 2021-07-15
AU2019417161B2 true AU2019417161B2 (en) 2023-06-15

Family

ID=71127864

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019417161A Ceased AU2019417161B2 (en) 2018-12-27 2019-12-04 Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease

Country Status (12)

Country Link
US (1) US12070442B2 (https=)
EP (1) EP3902525A4 (https=)
JP (1) JP2022516099A (https=)
KR (1) KR20210141448A (https=)
CN (1) CN113473970A (https=)
AU (1) AU2019417161B2 (https=)
BR (1) BR112021012492A2 (https=)
CA (1) CA3124945A1 (https=)
IL (1) IL284344A (https=)
MX (1) MX2021007709A (https=)
SG (1) SG11202106967QA (https=)
WO (1) WO2020139525A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7138103B2 (ja) 2016-11-29 2022-09-15 オキュリス エスエー 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造
WO2019060696A1 (en) * 2017-09-25 2019-03-28 Surface Pharmaceuticals, Inc. OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE
WO2022076398A1 (en) * 2020-10-07 2022-04-14 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
CA3124945A1 (en) 2018-12-27 2020-07-02 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
EP4670738A3 (en) 2019-07-01 2026-03-04 Oculis Operations Sàrl Method for stabilizing the ph of an aqueous composition comprising a drug
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
EP4469059A4 (en) * 2022-01-24 2026-01-21 Surface Ophthalmics Inc PHARMACEUTICAL COMPOSITIONS OF MYCOPHENOLIC ACID AND/OR BETAMETHASONE FOR THE TREATMENT OF EYE DISORDERS
JP2025538061A (ja) 2022-11-04 2025-11-26 クラリス バイオ インコーポレイテッド クロマカリムの局所眼内送達
EP4616843A1 (en) * 2024-03-13 2025-09-17 Iakov Mirkin Pharmaceutical composition for use in the treatment of ulcerative colitis and in the treatment of interstitial cystitis/bladder pain syndrome

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010041671A1 (en) * 2000-04-07 2001-11-15 Napoli Guido Di Ophthalmic formulations
US20050063996A1 (en) * 2003-09-19 2005-03-24 Gholam Peyman Ocular solutions
WO2006073786A2 (en) * 2004-12-30 2006-07-13 Bausch & Lomb Incorporated Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
US9789080B2 (en) * 2015-09-04 2017-10-17 Insite Vision Incorporated Ophthalmic formulations of mycophenolic acid
US10058616B2 (en) * 2012-02-10 2018-08-28 Tlc Biopharmaceuticals, Inc. Pharmaceutical compositions to reduce complications of ocular steroid

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2503563A1 (fr) 1981-04-09 1982-10-15 Pos Lab Composition pour collyre a base de sulfate de chondroitine a
US4863907A (en) 1984-06-29 1989-09-05 Seikagaku Kogyo Co., Ltd. Crosslinked glycosaminoglycans and their use
US4696917A (en) 1985-08-01 1987-09-29 Lindstrom Richard L Irrigation solution
CA2041828A1 (en) 1990-03-05 1992-11-04 Richard L. Lindstrom Viscoelastic solution
US5514686A (en) 1991-04-26 1996-05-07 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for eye diseases
US5518732A (en) 1995-02-14 1996-05-21 Chiron Vision, Inc. Bio-erodible ophthalmic shield
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
AU777915B2 (en) 1999-04-30 2004-11-04 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US6489335B2 (en) 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
CN1127955C (zh) 2000-07-07 2003-11-19 中山医科大学中山眼科中心 一种眼前段及眼表免疫相关性疾病治疗药物
DE10045343B4 (de) 2000-09-14 2005-05-12 Neuhann, Tobias, Dr.med. Verwendung einer wässrigen Lösung oder Suspension zum Heilen des Hornhautepithels
AU2002230504A1 (en) 2000-12-20 2002-07-01 Alcon Universal Ltd. Ophthalmic irrigating solution adapted for use in lasik surgery
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
GB0404693D0 (en) 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
WO2006044155A2 (en) 2004-10-01 2006-04-27 Lindstrom Richard L Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same
EP1814518A1 (en) 2004-11-23 2007-08-08 Alcon Inc. Triple natural polymer viscoelastic composition
US20070082841A1 (en) 2005-09-27 2007-04-12 Aciont, Inc. Ocular administration of immunosuppressive agents
DE102005055275A1 (de) 2005-11-17 2007-05-24 Ursapharm Arzneimittel Gmbh & Co. Kg Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
WO2007130364A2 (en) 2006-05-01 2007-11-15 Riolan Technologies, Inc. Compositions, methods, and kits for treating dry eye
US20080242646A1 (en) 2007-03-26 2008-10-02 Lessem Jan N Split dose corticosteroid therapy
JP5202986B2 (ja) 2007-09-14 2013-06-05 ロート製薬株式会社 コンタクトレンズ装着液
WO2009035033A1 (ja) 2007-09-14 2009-03-19 Rohto Pharmaceutical Co., Ltd. 眼科用組成物
JP2011505409A (ja) 2007-12-04 2011-02-24 ノバガリ ファーマ エスエー パルミチン酸デキサメタゾンのようなコルチコステロイドプロドラッグを含有する眼障害の治療用の組成物
US20100010082A1 (en) 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
US10201548B2 (en) 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US10980818B2 (en) 2009-03-06 2021-04-20 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
JP5595206B2 (ja) 2009-09-30 2014-09-24 ロート製薬株式会社 眼科用液体組成物
EP2308468A1 (en) 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
US20120264852A1 (en) 2009-10-29 2012-10-18 Colorado State University Research Foundation Polymeric materials including a glycosaminoglycan networked with a polyolefin-containing polymer
FR2962044B1 (fr) 2010-04-21 2013-02-22 Horus Pharma Emulsion lacrymimetique
US9233123B1 (en) 2010-12-07 2016-01-12 Richard L. Lindstrom Use of ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan
JP5925188B2 (ja) 2011-04-08 2016-05-25 ナノシータ株式会社 医薬製剤
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
ITPD20120098A1 (it) 2012-03-30 2013-10-01 Fidia Farmaceutici "nuove formulazioni faramaceutiche contenenti condroitin solfato e derivati dell'acido ialuronico"
ITMI20120896A1 (it) 2012-05-23 2013-11-24 Bongulielmi Reto Condroitina per uso in medicina
JP6452283B2 (ja) 2012-11-06 2019-01-16 ロート製薬株式会社 眼の異物感改善剤
EP2916827B1 (en) * 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
EP2937088B1 (en) 2012-12-21 2020-11-18 Tokushima University Composition having tissue repairing activity and utilization thereof
WO2015005458A1 (ja) 2013-07-10 2015-01-15 生化学工業株式会社 グリコサミノグリカン誘導体及びその製造方法
US20150100348A1 (en) 2013-10-08 2015-04-09 Ims Health Incorporated Secure Method for Health Record Transmission to Emergency Service Personnel
EP2979689A1 (en) 2014-07-29 2016-02-03 Sygene Technologies Composition for an eye drop and delivery system therefor
JP2016050181A (ja) * 2014-08-29 2016-04-11 大日本住友製薬株式会社 血管炎治療剤
ES2938482T3 (es) 2015-01-16 2023-04-11 Seikagaku Kogyo Co Ltd Sulfato de condroitina reticulado, composición que contiene el mismo y agente de tratamiento para enfermedad ocular
TWI773641B (zh) 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
US20190008891A1 (en) 2016-01-29 2019-01-10 Seikagaku Corporation Stabilized aqueous composition comprising chondroitin sulfate and hyaluronic acid
JP7288289B2 (ja) 2016-11-11 2023-06-07 ロート製薬株式会社 水性眼科組成物
KR20190095937A (ko) 2016-12-11 2019-08-16 시너지 더마톨로지 리미티드 설페이트화된 다당류를 포함하는 조성물
EP3558308A1 (en) 2016-12-22 2019-10-30 Novaliq GmbH Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
US20190008920A1 (en) 2017-05-19 2019-01-10 Ocugen, Inc. Ophthalmic compositions and methods of use
EP3624773A4 (en) * 2017-05-19 2021-04-07 Ocugen, Inc. OPHTHALMIC COMPOSITIONS AND METHOD OF USE
US20220143075A1 (en) 2017-09-25 2022-05-12 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
WO2019060696A1 (en) * 2017-09-25 2019-03-28 Surface Pharmaceuticals, Inc. OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE
US20230277557A1 (en) 2017-09-25 2023-09-07 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
JP7104553B2 (ja) 2018-03-30 2022-07-21 ロート製薬株式会社 眼科組成物
JP7417365B2 (ja) 2018-05-09 2024-01-18 ロート製薬株式会社 水性眼科組成物
TW202547536A (zh) 2018-05-09 2025-12-16 日商樂敦製藥股份有限公司 眼科組成物
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
CA3124945A1 (en) 2018-12-27 2020-07-02 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
JP6866412B2 (ja) 2019-02-28 2021-04-28 株式会社伊勢半 油中水型乳化化粧料
JP7758466B2 (ja) 2019-11-07 2025-10-22 ロート製薬株式会社 眼科組成物
US20230061058A1 (en) 2020-02-14 2023-03-02 Industry-Academic Cooperation Foundation, Yonsei University Hydrogel of chondroitin sulfate functionalized with phenol derivative and use thereof
JP2022157707A (ja) 2021-03-31 2022-10-14 ロート製薬株式会社 眼科組成物
WO2022240589A1 (en) 2021-05-12 2022-11-17 Schlumberger Technology Corporation Autonomous inflow control device system and method
EP4469059A4 (en) 2022-01-24 2026-01-21 Surface Ophthalmics Inc PHARMACEUTICAL COMPOSITIONS OF MYCOPHENOLIC ACID AND/OR BETAMETHASONE FOR THE TREATMENT OF EYE DISORDERS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010041671A1 (en) * 2000-04-07 2001-11-15 Napoli Guido Di Ophthalmic formulations
US20050063996A1 (en) * 2003-09-19 2005-03-24 Gholam Peyman Ocular solutions
WO2006073786A2 (en) * 2004-12-30 2006-07-13 Bausch & Lomb Incorporated Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
US10058616B2 (en) * 2012-02-10 2018-08-28 Tlc Biopharmaceuticals, Inc. Pharmaceutical compositions to reduce complications of ocular steroid
US9789080B2 (en) * 2015-09-04 2017-10-17 Insite Vision Incorporated Ophthalmic formulations of mycophenolic acid

Also Published As

Publication number Publication date
KR20210141448A (ko) 2021-11-23
AU2019417161A1 (en) 2021-07-15
EP3902525A4 (en) 2022-09-28
EP3902525A1 (en) 2021-11-03
MX2021007709A (es) 2021-12-15
BR112021012492A2 (pt) 2021-09-08
SG11202106967QA (en) 2021-07-29
CN113473970A (zh) 2021-10-01
WO2020139525A1 (en) 2020-07-02
CA3124945A1 (en) 2020-07-02
JP2022516099A (ja) 2022-02-24
US20220071945A1 (en) 2022-03-10
US12070442B2 (en) 2024-08-27
IL284344A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
AU2019417161B2 (en) Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US11766421B2 (en) Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US10561607B2 (en) Pharmaceutical compositions comprising gels and methods for fabricating thereof
US20230277557A1 (en) Pharmaceutical kits and their use for treating dry eye disease
TWI544934B (zh) 含有氟喹諾酮抗生素藥物之經改良藥學組成物
US20220143075A1 (en) Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US20110144027A1 (en) Pharmaceutical compositions for promoting wound healing
US20170112936A1 (en) Pharmaceutical compositions comprising gels and methods for fabricating thereof
JP2025513090A (ja) 眼疾患の治療のためのミコフェノール酸及び／又はベタメタゾンの医薬組成物
AU2025203019A1 (en) Ophthalmic Compositions Containing A Nitric Oxide Releasing Prostamide
CA3250770A1 (en) MULTIDOSE OPHTHALMIC COMPOSITIONS
WO2022076398A1 (en) Pharmaceutical kits and their use for treating dry eye disease
US20200155450A1 (en) Pharmaceutical compositions comprising gels and methods for fabricating thereof
US8679511B2 (en) In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
US20230158045A1 (en) Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders
RU2781022C2 (ru) Офтальмологические композиции, содержащие простамид, высвобождающий окись азота
HK40018890B (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
HK40018890A (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
TW202329958A (zh) 西維美林水溶液組合物和使用方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired